GlassScriptPhysician profile
Stephanie Wei Lai
NPI 1275195901
$4,383.10
in general payments reported to CMS, 2019-2025
27 companies · $919 in 2025
The $919 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.71 · 2020: $210 · 2021: $488 · 2022: $546 · 2023: $697 · 2024: $1,493 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,018.69 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $965.48 | 2020-2025 | |
| Pfizer INC. | $551.83 | 2020-2025 | |
| Janssen Biotech, INC. | $350.98 | 2023-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $346.98 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $253.68 | 2020-2025 | Taltz, Ebglyss |
| Dermavant Sciences, INC. | $233.98 | 2024 | Vtama |
| Leo Pharma INC. | $230.30 | 2023-2025 | Adbry |
| Ucb, INC. | $195.70 | 2022-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $186.05 | 2020-2025 | |
| Paratek Pharmaceuticals, INC. | $148.04 | 2022-2024 | Nuzyra |
| Galderma Laboratories, L.P. | $141.41 | 2025 | Nemluvio, Aklief |
| Genzyme Corporation | $120.57 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $104.17 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $99.29 | 2023-2025 | Zoryve |
| Amgen INC. | $73.82 | 2023-2025 | Otezla, Otezla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $73.70 | 2024-2025 | Sotyktu |
| Dermira, INC. | $48.92 | 2020-2021 | |
| Incyte Corporation | $41.25 | 2023-2024 | Opzelura |
| Verrica Pharmaceuticals INC. | $38.50 | 2024 | Ycanth |
| Janssen Pharmaceuticals, INC | $30.71 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.86 | 2021 | |
| Epi Health, LLC | $27.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.74 | 2024 | Spevigo |
| Journey Medical Corporation | $17.69 | 2022 | |
| Mayne Pharma Commercial LLC | $17.60 | 2025 | |
| Organon LLC | $17.57 | 2023 | Hadlima |
| Organogenesis INC. | $14.12 | 2024 | Affinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.